Literature DB >> 6936055

Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity.

T J Myers, F R Rickles, C Barb, M Cronlund.   

Abstract

Plasma fibrinopeptide A (FPA) levels were determined in 20 unselected adult patients with acute nonlymphocytic and lymphocytic leukemia. The mean FPA level in patients with active disease (15.0 ng/ml) was significantly higher than during clinical remission (2.4 ng/ml, p less than 0.01). Elevated FPA levels were observed in patients with all morphological forms of acute leukemia. In the group of patients in clinical remission, 20/47 FPA values remained elevated beyond the normal range, suggesting that low-grade intravascular coagulation was present even when no leukemic cells were observed. Sequential studies revealed reduction of FPA levels to the normal range in five patients who entered clinical remission after chemotherapy and rapid elevation of the levels in eight patients who entered relapse after clinical remission. FPA levels rose significantly in five patients studied during induction chemotherapy. Thus, subclinical activation of blood coagulation, as defined by elevation of plasma FPA level, may occur commonly in acute leukemia. Plasma FPA generation may relate to leukemic disease activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6936055

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Whole blood procoagulant activity in breast and colorectal cancer.

Authors:  H Mellor; I Taylor; S Roath; J L Francis
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

2.  Elevated thrombin-antithrombin III complex concentrations in patients with gynaecological malignancy.

Authors:  G Tatra; A Reinthaller
Journal:  Klin Wochenschr       Date:  1991-02-06

3.  Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.

Authors:  I Pabinger; P Bettelheim; R Dudczak; W Hinterberger; P A Kyrle; H Niessner; I Schwarzinger; W Speiser; K Lechner
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

4.  Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis.

Authors:  W Speiser; I Pabinger-Fasching; P A Kyrle; S Kapiotis; A Kottas-Heldenberg; P Bettelheim; K Lechner
Journal:  Blut       Date:  1990-11

5.  Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.

Authors:  C S Greenberg; C C Miraglia; F R Rickles; M A Shuman
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

Review 6.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

7.  Coagulopathy in the prostate cancer patient: prevalence and clinical relevance.

Authors:  A S Adamson; J L Francis; R O Witherow; M E Snell
Journal:  Ann R Coll Surg Engl       Date:  1993-03       Impact factor: 1.891

Review 8.  Hemostatic alterations in cancer patients.

Authors:  F R Rickles; M Levine; R L Edwards
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

9.  Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukaemia.

Authors:  F Rodeghiero; G Castaman; G Soffiati; R Quaglio; S Castronovo; S Cortesi; E Dini
Journal:  Blut       Date:  1989-08

10.  Fibrinogen--proteolysis in acute myelogenous leukemia (AML).

Authors:  T Eckhardt; M Koch
Journal:  Blut       Date:  1986-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.